Grants for Exclusive - see details - Health

The purpose of this program is to provide substance use prevention, substance use disorder (SUD) treatment, HIV, and viral hepatitis prevention and treatment services for racial and ethnic individuals vulnerable to a SUD and/or mental health condition, HIV, viral hepatitis, and other infectious disease (e.g., sexually transmitted infections). Recipients will be expected to take a syndemic approach to SUD, HIV, and viral hepatitis by providing SUD prevention and treatment to racial and ethnic individuals at risk for or living with HIV.

This grant provides financial support to large community water systems in New Hampshire for conducting lead service line inventories and developing replacement plans to ensure safe drinking water.

This funding opportunity provides financial support to rural United Methodist churches in North Carolina for outreach programs, church development, and leadership initiatives aimed at enhancing community health and congregational growth.

The aim of USAID/Namibias Key Populations - Resilience, Innovation, Sustainability, and Empowerment (KP-RISE) activity is to provide innovative HIV service delivery, build capacity of KP-led organizations, promote policy, legal and societal environment to increase access to health services, and to use data for program improvement and advocacy. USAID desires to support Activities which offer high impact prevention options to those that are HIV negative, initiate those who are HIV+ and not yet on treatment, reinitiate those who are HIV positive and whose treatment has lapsed, and provide care and support for all.At this time USAID has not selected a type of obligating instrument for the anticipated activity. In the spirit of co-design, feedback provided to this RFI will be utilized in the finalization of the activitys design.

The USAID THRIVE activity aims to contribute to achieving sustained epidemic control by improving the health and wellbeing of children living with HIV and reducing the risk of HIV infection among vulnerable children, adolescents, and caregivers. The activity will provide a suite of comprehensive services to build resilience and mitigate the multiple, layered vulnerabilities faced by these sub-populations. The target population for THRIVE activity is children and adolescents living with HIV (CALHIV), children whose caregivers are living with HIV (CPLHIV), HIV exposed infants (HEI), children of key populations (CKP), survivors of sexual violence against children (SVAC), and high-risk adolescent boys and girls, including out of school children.

The United States Agency for International Development (USAID) is seeking applications for a cooperative agreement from qualified entities to implement the USAID/Kenya and East Africa Social and Behavior Change Activity.The full announcement may be downloaded under the Related Documents tab.

The Los Angeles County Department of Economic Opportunity (DEO) is launching the Commercial Acquisition Fund (CAF) to provide grants to qualifying nonprofit organizations to support the acquisition of vacant or abandoned land and buildings in designated communities that were most negatively impacted by the COVID-19 pandemic. Donor Name: Los Angeles County Department of Economic Opportunity State: California County: Los Angeles County (CA) Type of Grant: Grant Deadline: 05/20/2024 Size of the Grant: More than $1 million Grant Duration: Grant Duration Not Mentioned Details: The program goal is to acquire vacant or abandoned commercial properties in Los Angeles County, particularly those identified as highest and high need areas per the County’s COVID-19 Vulnerability and Recovery Index in the Equity Explorer Tool.  Funding Information The CAF is funded by the County, with $10 million in American Rescue Plan Act (ARPA) funds and will be awarded as recoverable grants, ranging from $500,000 to $2,000,000. Eligibility Criteria To be eligible to receive these funds you must meet the following requirements to become a Qualifying Acquisition Entity (QAE): Be an active nonprofit (including community development corporations / community land trusts). Be a LA County certified business partnered with a non-profit. Not be disbarred by federal, State, or local government entity or have unresolved violations noted in the County’s contracting database. For more information, visit DEO.

Operating Grants I & II provide unrestricted, operating support to Long Beach-based arts and cultural organizations whose primary mission is to collect, preserve, present and/or commission exemplary works of art (e.g. visual art exhibitions, theatre, dance and/or musical performances). Donor Name: Arts Council for Long Beach State: California City: Long Beach Type of Grant: Grant Deadline: 06/14/2024 Size of the Grant: $10,000 to $100,000 Grant Duration: Grant Duration Not Mentioned Details: Works of art must be of regional significance, for the benefit of the general public and provide educational opportunities that enable audiences to better understand and appreciate the arts. Organization budgets must be over $250,000 annually. Program Goals  Artistic Encourage the development of long-term, quality artistic programs Support the development of innovative, creative and unique projects or programming that challenges audiences and participants Organizational Management Support best practices in organizational management, including long-term planning, accountability, fund development, transparency, evaluation, appropriate qualifications of board and staff and other professionals, and overall fiscal health Community Impact Support organizations that identify community needs and demonstrate a commitment and ability to meet needs through planning and program delivery Support the development of new audiences Support organizations that foster and enhance tourism and/or work to create a larger market or audience for an artistic discipline. Funding Information Grants awarded for OPG I with award amounts ranging from $5,000 to $8,000. Grants awarded for OPG II with award amounts ranging from $18,000 to $25,000. Who may apply? Eligible applicants are Long Beach-based arts and cultural organizations whose primary mission is to collect, preserve, present and/or commission exemplary works of art (e.g., art exhibitions, film and/or media arts, theatre, dance and/or musical performances). Eligible applicants produce works of art that are of regional significance, for the benefit of the general public and that provide educational opportunities that enable audiences to better understand and appreciate the arts. For more information, visit ACLB.

If you are a direct-market agribusiness located in Albemarle County, you’re invited to apply for an Albemarle Agribusiness Resiliency Grant. Donor Name: Albemarle County State: Virginia County: Albemarle County (VA) Type of Grant: Grant Deadline: 05/10/2024 Size of the Grant: $10,000 to $100,000 Grant Duration: Grant Duration Not Mentioned Details: This grant supports agribusinesses who are experiencing longer-term impacts of the pandemic, which includes higher costs due to inflation and rising interest rates. These impacts result in higher cost of capital overall and less capital to fund growth and reinvestment. To help offset these impacts, Albemarle County will distribute a second round of Agribusiness Resiliency Grants. Grants are available for direct-market agribusinesses – those selling products to restaurants, caterers, local stores; orchards, wineries, and cideries; or at farmers markets. Funding Information  The total budget for this round is $60,000 and staff anticipates making 3-8 grants total. Grant funding may be use for: New capital investments like machinery, tools, other business equipment. Expenses incurred to advance sustainable agricultural practices since July 1, 2022. Expenses incurred to enhance public health, safety, welfare of employees or visitors since July 1, 2022. Expenses incurred to comply with state or local regulations since July 1, 2022. Up to 20% of awarded funds may be used for advertising/marketing. Criteria  Must have a County business license and be in good standing with the County.  Proof of payment must be provided for all eligible expenses.  Grant awardees will be required to schedule a farm visit with the Economic Development Office prior to June 30, 2024.  For more information, visit Albemarle County.

The ITP ASH 2024 grant initiative, offered by SANOFI, is designed to identify and fund projects that aim to close significant healthcare gaps related to the treatment and management of Immune Thrombocytopenia (ITP). ITP is a rare blood disorder characterized by a significantly reduced platelet count, leading to a heightened risk of bleeding and serious health complications such as thrombosis and hematologic malignancy. The chronic nature of ITP often results in a diminished quality of life for patients, manifesting in anxiety, fatigue, and depression due to ongoing concerns about bleeding risks and ineffective current therapies. SANOFI is particularly interested in supporting educational and therapeutic strategies that promise to enhance the clinical handling of ITP, focusing on innovative treatment methodologies and educational activities that can lead to improved patient outcomes. Proposals are invited for projects including, but not limited to, live symposiums at medical conferences, enduring materials for broader educational reach, and both accredited and non-accredited Independent Medical Education (IME) activities. A budget cap of $425,000 is set for the grant, with a strong preference for proposals that incorporate evidence-based approaches and demonstrate potential to address knowledge gaps among healthcare providers, thus improving treatment practices.

The FY24 PCRP Early Investigator Research Award supports prostate cancer-focused research opportunities for individuals in the early stages of their careers under the guidance of one or more designated mentors. This opportunity allows early-career investigators to develop a research project, investigate a problem or question in prostate cancer research, and further their intellectual development as prostate cancer researchers of the future. All application components for the FY24 PCRP Early Investigator Research Award are to be written by the Principal Investigator (PI), with appropriate direction from the mentor(s).Key elements of this award mechanism are as follows: Principal Investigator: The postdoctoral investigator is considered the PI of the application and must exhibit strong potential for and commitment to pursuing a career as an investigator at the forefront of prostate cancer research; however, the PI is not required to have previous prostate cancer research experience. The PI must have 3 years or less of postdoctoral research experience (excluding clinical residency or clinical fellowship training) as of March 31, 2025. The PCRP strongly encourages applications from PIs who demonstrate a commitment to pursuing a career focused on prostate cancer health disparity research. Mentor(s): Applications must include at least one mentor appropriate to the proposed research project who has experience in prostate cancer research and mentoring as demonstrated by a record of active funding, recent publications, and successful mentorship. The primary mentor can be a junior faculty member, in which case the PI is encouraged to include a secondary mentor with a more robust track record in prostate cancer research and mentorship. Applications that focus on prostate cancer health disparity should include at least one mentor with experience in prostate cancer health disparity research. The selected mentor(s) should also demonstrate a clear commitment to the development of the PI toward independence as a prostate cancer researcher. Research Approach: Proposed research ideas are required to address one or more of the FY24 PCRP Overarching Challenges. Projects that specifically address the FY24 PCRP Overarching Challenge to advance health equity and reduce disparities in prostate cancer are strongly encouraged. The scientific rationale and experimental methodology should demonstrate in-depth analysis of the research problem presented. The feasibility of the research design and methods should be well defined, and a clear plan should be articulated as to how the proposed goals of the project can be achieved. Inclusion of preliminary data relevant to prostate cancer and the proposed project is encouraged but not required. Any preliminary data provided should be from the PI, mentor(s), or member(s) of the collaborating team. Additionally, required resources should be identified and supported through documentation. Research involving human subjects and human anatomical substances is permitted; however, clinical trials are not allowed under this funding opportunity. Researcher Development Plan: The PI must outline an individualized, prostate cancer-focused researcher development plan, which should include a clearly articulated strategy for acquiring the necessary skills, competence, and expertise that will enable the PI to successfully complete the proposed research project and foster the PIs development as an independent prostate cancer researcher. An environment appropriate to the proposed mentoring and research project must be clearly described, although any deficiencies of resources and/or mentorship at the PIs institution can be mitigated through collaboration(s) with other institutions. If the PI will be utilizing resources at another institution to successfully complete the proposed project, then the PI is strongly encouraged to designate a co-mentor at the collaborating institution.Investigators are strongly encouraged to incorporate the following components into their study design, where appropriate, in order to maximize the potential impact of the proposed research project: authentication of proposed cell lines; statistical rigor of preclinical animal experiments; and incorporation of experiments to assess clinical relevance and translatability of findings. Studies utilizing data derived from large patient studies that include long-term health records, biospecimen repositories, and pre-existing research and apply state-of-the-art genomic and/or proteomic analysis, bioinformatics, and/or mathematical models to such data are also encouraged. Investigators are highly encouraged to provide a letter of support indicating access to and the availability of any resources required to support the study.A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, the CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 PCRP priorities.Innovative research involving nuclear medicine and related techniques to support early diagnosis, more-effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (http://www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies.Clinical trials are not allowed. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated direct costs budgeted for the entire period of performance for an FY24 PCRP Early Investigator Research Award should not exceed $300,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $6.24M to fund approximately 13 Early Investigator Research Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

This grant opportunity, offered by Sanofi, aims to address gaps and provide educational resources related to the diagnosis and treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP). CIDP is a heterogeneous, immune-mediated neuropathy characterized by demyelination of motor and sensory nerves, leading to various clinical challenges. Sanofi seeks proposals for educational programs, particularly those that can effectively recap information from the 2024 Peripheral Nerve Society Annual Meeting and offer independent medical education (IME) activities. Programs should focus on key evidence-based data and offer recommendations to healthcare providers dealing with CIDP, particularly in areas such as treatment options, clinical challenges, and the role of complement therapeutics in CIDP care.

This grant from Sanofi's Rare Blood Disorders Medical Affairs department focuses on medical education programs addressing Immune Thrombocytopenia (ITP). The grant aims to support independent medical education (IME) activities that recap highlights from EHA 2024 and ISTH 2024 conferences on ITP, emphasizing enduring programs, accredited or non-accredited IME activities, and digital or omnichannel formats. Proposals should address existing healthcare gaps in the treatment and management of ITP, improving clinician knowledge and patient outcomes. The maximum grant request is $150,000, with a focus on comprehensive interventions that address knowledge and performance gaps in ITP treatment. Proposals should cover target audience generation, learning objectives, educational methods, faculty recruitment, program evaluation, and budget planning.

U.S. Embassy Nigeria through the U.S. Presidents Emergency Plan for AIDS Relief (PEPFAR) Coordination Office of the Bureau of Global Health Security and Diplomacy at the U.S. Department of State announces an open competitive opportunity for organizations to apply for funding to implement community-led monitoring or a virtual spaces intervention among priority populations for HIV prevention and treatment, including Key Populations (KP) and Adolescent and Young People (AYP). For HIV to no longer be a public health threat by 2030 in Nigeria, the populations at highest risk must know their HIV status, receive lifesaving HIV prevention and treatment, and reach viral suppression if they are HIV-positive. Data show that HIV prevention and treatment efforts should be focused on AYP and KPs. Key Populations include men who have sex with men, transgender individuals, sex workers, people who inject drugs (PWID), and people in prisons and other closed settings. Under this opportunity, the PEPFAR Coordination Office seeks to address pillar 1 of the 5x3 strategy, health equity for priority populations. Youth make up a significant proportion of the more than 32.9 million Nigerians reported to be active users of social media. AYP-led CSOs in the country have identified a gap with the lack of structured sexual health and HIV messaging and interventions on these platforms. Virtual online space is a digital environment that enables people to, socialize, interact, and gather information using available technologies and non-necessarily requiring a physical space to operate. Interventions on a virtual space may include, but not be limited to phone services such as calls and messaging, mobile applications, websites, and social media channels. Through Virtual Spaces Interventions, PEPFAR Nigeria intends to address the gaps in the use of online platforms and spaces by meeting KP and AYP where they are; providing them with HIV and other relevant health information; facilitating referrals and linkages to health facilities for person-centered HIV prevention, treatment, and other health care services. Prioritizing these spaces as a compliment of existing health systems in the on-going efforts to increase program reach among AYP and KPs, and to use this space to facilitate health promotion, HIV testing and case-finding, and drive access to other health services in a confidential manner. This program seeks to increase access to quality, concise and accurate HIV and health related messaging, facilitate active referrals and linkages to spaces and locations which can provided access to strategic HIV and other health services for prevention, treatment and care interventions targeted at AYP and KPs by leveraging on virtual spaces utilized by adolescents and young persons. The program will support community-led monitoring efforts among AYP and KP-led groups using platforms such as iMonitor + to ensure that HIV positive individuals among these priority populations are receiving high quality care and treatment services, identify any challenges, barriers, and/or gaps to care, and to report findings to PEPFAR to inform service delivery.

CDS projects align with SAMHSA's mission to lead public health and service delivery efforts that promote mental health, prevent substance misuse, and provide treatments and supports to foster recovery while ensuring equitable access and better outcomes. Recipients are expected to fully implement the projects that were approved by Congress. With this program, SAMHSA aims to award resources enacted in the FY 2024 Further Consolidated Appropriation Act.

This Notice of Funding Opportunity (NOFO) announces the opportunity to apply for funding under the fiscal year (FY) 2024 Behavioral Health Service Expansion (BHSE) program. BHSE will support health centers to increase access to behavioral health services through starting or expanding mental health and substance use disorder (SUD) services.

The Mississippi Delta is a historically and culturally rich region of the United States. The architecture, French, Spanish, British, and German, is as diverse as the people whose origins are European, Native American, Spanish, African, and more. But for all its cultural wealth, there is a poverty of health and healthcare in the region. Residents of the 18-county region contend with persistent poor health outcomes compounded by challenges to attaining preventive services and care, poor quality of care, and stagnant opportunity structures, particularly as it relates to cardiovascular disease (CVD).Roughly 1 in 10 (9.9% 28.6 million) adults in the US have at least 1 type of CVD, including coronary heart disease, heart failure, or stroke. This number excludes hypertension, a risk factor for and cause of CVD but not a type of CVD. However, hypertension or high blood pressure is a critical risk factor for stroke. An estimated 120 million American adults (48.1%) have it, most (3 in 4) dont have it controlled, and 1 in 5 adults is unaware they have hypertension.In 2012 CVD, particularly heart disease, was the leading cause of death in the Delta (244.4 deaths per 100,000). The regions residents experience age-adjusted death rates due to heart disease, stroke, and other CVDs that are considerably higher than national rates and the rest of Mississippi. According to the 2018 Cardiovascular Health Examination Survey (CHES) in the Mississippi Delta, the adjusted overall prevalence of hypertension among adults in the region 18 and older was 42.8%.The persistence of these outcomes in the Delta is attributable to modifiable CVD conditions and risk factors, such as high blood pressure, high cholesterol, coronary heart disease, COPD, chronic kidney disease, diabetes, and stroke. To sufficiently address these conditions, interventions must include evidence-based and practice-based approaches that are innovative and tailored to the unique challenges and strengths of the 18-county MS Delta Region. These interventions are needed in strategies that are focused on health systems, team-based care, and linkages to community resources and clinical services that address the social conditions that contribute to the prevalence of CVD in the MS Delta Region. This cooperative agreement builds from lessons learned from previous iterations. It focuses on policy, systems, and environmental changes that impact clinical and community settings and lifestyle changes that reduce uncontrolled blood pressure and CVD within the MS Delta Region.

The Rural and Underserved Clinical Rotations grant, authorized by Minnesota Statutes Sec 144.1505, aims to enhance health professional training sites, including those for physicians, physician assistants, nurses, pharmacists, dentists, dental therapists, and mental health professionals. This program supports the expansion of existing clinical training programs to include rural and underserved rotations or specialized training tracks, focusing on primary care settings in rural communities. This expansion is intended to strengthen the healthcare workforce and improve access to healthcare in these communities.

The "2024 Workplace Safety Grants for Health Care Entities" program is designed to enhance safety in healthcare environments through grants supporting projects focused on training staff in de-escalation and positive support services and increasing safety measures. Authorized by 2023 Session Law, Chapter 70, Article 4, Section 109, it aims for long-term improvements in safety and stability for both staff and patients. The program will distribute funds competitively, with anticipated multiple funding cycles depending on fund availability. The total program funding allocated is $4,400,000, with this cycle's estimated amount at $1,500,000 aimed to support around 30 awards.

The goal of USAID/Cambodias new five-year community tuberculosis (TB) activity is to accelerate TB case finding and case holding activities to maximize TB outcomes among Cambodians, including vulnerable populations such as Indigenous People. This Activity will build on USAIDs previous investments in community TB control, including the USAID Community Mobilization Initiatives to End Tuberculosis (COMMIT) activity, recommendations from the COMMITs mid-term evaluation, and lessons learned from stakeholders; and further contribute to the National TB Strategic Plan to End TB (2021-2030), World Health Organizations (WHO) End TB Strategy, and USAIDs Global TB Strategy 2023 - 2030. This Activity will focus on improving and streamlining the implementation of the End TB strategy at the community level while strengthening longer-term systems and capacity for: improving access to and demand for high quality TB services and advancing their integration within national health systems, creating an enabling private sector environment for TB control and the provision of TB services, and improving TB Management Information System (MIS) systems and data use, to provide better and more sustainable TB services.